- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06537362
Mouthpiece With Integrated Cheek Support vs. Manual Cheek Support During Respiratory Oscillometry (COMICUSROM)
Comparative Evaluation of the Use of a Mouthpiece With Integrated Cheek Support vs. Manual Cheek Support During Respiratory Oscillometry Measurements
The study aims to evaluate the measurement accuracy of respiratory impedance during oscillometry (or Forced Oscillation Technique - FOT) under the following conditions: 1)The subject's cheeks are manually supported by an expert (Gold Standard method), 2) The subject's cheeks are supported by an integrated cheek support in the mouthpiece.
It is a prospective, randomized, cross-over study on Subjects who will present themselves at the offices of the participating doctors, aged between 5 and 75 years. The primary outcome is to Compare the respiratory impedance measurements under the two measurement conditions. Secondary Objectives are to: i)evaluate the patient's comfort during the measurement with the cheek support and compare this comfort to the gold standard condition; ii) assess the maximum and minimum face dimensions of the recruited subjects that allow for effective and comfortable cheek support; iii) evaluate the type and frequency of measurement errors introduced by the use of the integrated cheek support in the mouthpiece.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design: prospective, randomized, cross-over study. Study population: Subjects who will present themselves at the participating doctors' offices. Inclusion criteria: subjects aged between 5 and 75 years. Exclusion criteria: Subjects unable to follow the study procedures or with any physical or mental condition deemed unsuitable by the doctor will be excluded from the study.
Study protocol: the measurement protocol will consist of measuring the subject's facial morphological parameters and respiratory impedance parameters, followed by the administration of a questionnaire on perceived comfort. The procedure will be performed in a seated position.
Measurements:
- Morphological Parameters Using a sliding caliper. The following anatomical distances will be measured on the seated subject, looking straight ahead with teeth together, facial muscles relaxed, and mouth closed: a) BIGONIAL WIDTH: The straight-line distance between the right and left angles of the mandible; b) LIP LENGTH: The straight-line distance between the right and left corners of the closed mouth."
Respiratory Impedance. The impedance measurement will be performed using the Resmon FIRST (Restech srl, Milan, Italy). Repeated measurements will be taken for each subject three times (TRIPLICATE) over 10 breaths with mono-frequency oscillations at 5 Hz. The enrolled subjects will perform the following measurements in a random order:
- One TRIPLICATE session of respiratory impedance with cheeks supported by study personnel.
- One TRIPLICATE session of respiratory impedance with cheeks supported by the cheek support. The study personnel will record any operator errors associated with preparing and using the cheek support on the enrolled participants.
- Comfort Evaluation Questionnaire. At the end of the measurements, each participant will be asked to complete a comfort evaluation questionnaire regarding their experience during the procedure. Currently, no commercial devices are similar to the cheek support being tested. Therefore, the questionnaire is a modified version of a questionnaire previously used to evaluate the comfort of mechanical respirators worn on patients' faces during the coronavirus disease (COVID-19) period (Respirator Comfort, Wearing Experience, and Function Instrument (R-COMFI)3). The questionnaire aims to cover sensations of discomfort and general impressions of using the mouthpiece with cheek support during respiratory oscillometry measurements.
Sample size: The total number of subjects to be enrolled in the study is 55. This number was determined based on the following assumptions:
- Type-I error (α) = 5%, study power (1-β) >= 80%
- Uniform distribution of subjects in the following age groups: 6-17, 18-75 years
- Range of Resistance (Rrs) = 2...15 cmH2O/(L/s)
- Range of Reactance (Xrs) = 0...-14 cmH2O/(L/s)
- Minimum expected differences: the investigators set the minimum expected difference at 10% with a minimum value of 0.1 cmH2O/(L/s) (see table below)
- Expected standard deviation of variation: the investigators assume the expected standard deviation of variation to be the standard deviation of the short-term repeatability of oscillometry measurements reported in the literature (see table below)
- Dropout rate = 10%
Data analysis:
Comparison between the Cheek Holder Mouthpiece and Operator Support. The differences between the measurements taken with manual cheek support and those taken with the cheek holder will be analyzed. The two methods will be considered equivalent if the mean difference between the results and the 95% confidence interval of the Deming regression fall within the expected short-term variability of the technique for the tested population. Specifically:
- For Rrs, a difference within 17% in adults and 27% in children, with a minimum acceptable difference of 1 cmH2O/(L/s), will be considered acceptable.
- For Xrs, a difference within 37% in adults and 40% in children, with a minimum acceptable difference of 0.5 cmH2O/(L/s), will be considered acceptable.
- Evaluation of Patient Comfort. The comfort of each patient will be assessed using a scoring system associated with specific questions. The total scores obtained with the two methodologies will be compared using a paired t-test or alternative tests for non-parametric distributions.
- Evaluation of the Impact of Face Dimensions on FOT Test Accuracy. The impact of face dimensions on the effectiveness of the cheek holder support will be assessed by investigating the presence of a correlation between the differences in results obtained with the cheek holder and those obtained with manual support by the physician relative to lip length (LIP) and bigonial width. The type and frequency of user errors will be summarized for the entire population and for each age group using descriptive statistics (mean and standard deviation or median and ranges, as appropriate).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Raffale Dellaca, PhD
- Phone Number: 0223999005
- Email: raffaele.dellaca@polimi.it
Study Contact Backup
- Name: Chiara Veneroni, PhD
- Phone Number: 0223999024
- Email: chiara.veneroni@polimi.it
Study Locations
-
-
-
Bergamo, Italy
- Recruiting
- Allergy and Pneumology Outpatient Clinic
-
Contact:
- Marcello Cottini
- Email: cottinimarcello@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- subjects aged between 5 and 75 years
Exclusion Criteria:
- Subjects unable to follow the study procedures or with any physical or mental condition deemed unsuitable by the doctor will be excluded from the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
During oscillometry measures, the subject's cheeks are manually supported by an expert (Gold Standard method)
|
|
|
Experimental: Cheek Holder
During oscillometry measures, the subject's cheeks are supported by an integrated cheek support in the mouthpiece
|
A cheek support integrated into the mouthpiece is used for the measures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
impedance measurements
Time Frame: within session (about 15 min)
|
Compare the respiratory respiratory resistance (cmH2O*s/L) and reactance (cmH2O*s/L) at 5 Hz under the two measurement conditions
|
within session (about 15 min)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluate patient's comfort during the measurement with the cheek support
Time Frame: within session (about 15 min)
|
evaluate the patient's comfort during the measurement with the cheek support and compare this comfort to the gold standard condition as quantified by the questionnaire
|
within session (about 15 min)
|
|
face dimensions allowing for effective and comfortable cheek support
Time Frame: within session (about 15 min)
|
assess the maximum and minimum face dimensions (to lip length and bigonial width) of the recruited subjects that allow for effective and comfortable cheek support as detailed in the Data Analysis section
|
within session (about 15 min)
|
|
evaluate the type and frequency of measurement errors
Time Frame: within session (about 15 min)
|
evaluate the type and frequency of measurement errors introduced by the use of the integrated cheek support in the mouthpiece.
|
within session (about 15 min)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CheekHolder
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Function Decreased
-
Sir Run Run Shaw HospitalRecruitingLung Function DecreasedChina
-
Deraya UniversityCompletedLung Function DecreasedEgypt
-
The Second Hospital of Shandong UniversityRecruiting
-
China-Japan Friendship HospitalCompleted
-
Rigshospitalet, DenmarkUnknownPain | Decreased Lung Function | Delayed DischargeDenmark
-
University Hospital Inselspital, BerneCompletedLung Diseases | Surgery | Lung Function DecreasedSwitzerland
-
Mahidol UniversityCompletedOSA | COPD | Lung Function DecreasedThailand
-
Yun LongUnknownCritical Illness | ICU Acquired Weakness | Lung Function DecreasedChina
-
Prince of Songkla UniversityCompletedBronchiectasis | Lung Function Decreased | Exacerbation CopdThailand
-
University of RochesterNot yet recruitingHealthy | Breathing | Lung Function Decreased | MRI ImagingUnited States
Clinical Trials on Mouthpiece with cheek-holder
-
Rush University Medical CenterLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTerminatedTransmission, Patient-ProfessionalUnited States
-
Nantes University HospitalTerminated
-
Vectura LimitedCompleted
-
Tanta UniversityRecruiting
-
Ege UniversityCompletedRegenerative EndodonticsTurkey
-
National Cancer Institute (NCI)NRG OncologyCompletedMalignant Ovarian Epithelial Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein ProficientUnited States
-
GOG FoundationNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States